Thus, there is some evidence that cyclin-dependent kinase inhibitors (CDKI) gene mutations can lead to parathyroid tumor development, particularly the mutations in CDKN1B/p27 gene [27]. The gene discussed is CDKN1B; the disease is tumor of parathyroid gland.